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INTRODUCTION 
Therapeutic proteins are the fastest-growing 
source of new therapies in the biopharmaceutical 
industry resulting in a demand for more efficient 
protein expression systems. 
Yeast-based expression systems offer a variety of 
advantages: shorter fermentation times, cheaper 
operating costs, chemically defined media, no viral 
contamination, higher protein titers, and much 
shorter development times from gene to protein. 
However, for the production of glycoproteins for 
human use, native highmannose yeast 
glycosylation is not suitable and therefore 
represents a major limitation for yeast based 
protein expression systems. 
  
 
 
 
 
 
 
 
OBJECTIVES 
 obtaining a humanized Pichia pastoris 
strain able to produce N-gycosilated 
proteins with proper folding, 
pharmacokinetic stability, and efficacy.  
 application in the production of monoclonal 
antibodies. 
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N-GLYCOSYLATION IN YEAST AND 
HUMAN 
Fig.8.Glycoengineered yeast cultivation platform.[8] 
Fig.1. Pichia pastoris yeast cells. [1] 
Fig.3. Schematic workflow of the knockout of OCH1 using a flipper cassette. [3] 
REBUILDING THE HUMAN SECRETORY 
PATHWAY 
Fig.4. A working model for the cellular 
distribution of glycosyltransferases 
throughout the secretion pathway. [4] 
• Screening of a 
combinatorial 
library of α-1,2 
mannosidases. 
• Screening of a library 
of catalytic domains 
encoding N-acetyl-
glucosaminyltransfer
ase I (GnTI) fused to 
a library of yeast 
localization signals. 
• Use of the 
combinatorial library 
approach to 
introduce 
mannosidase II and 
GnTII. 
A galactosyl transferase should 
add one galactose sugar onto 
every branch. The mutant strain 
capable of producing complex 
human N-glycans was 
accomplished through deletion of 
PpALG3 and  expression of GnT 
II and GalT. 
 
GALACTOSYLATION 
SIALIC ACID TANSFER 
The transfer of sialic acid onto terminal β-1,4 
galactose sugars of complex glycoproteins requires a 
library with catalytic domains, a library with several 
N-terminal fragments for the location and a pool of 
CMP-sialic acid available (not available in yeast).  
Therefore a pathway to produce CMP-sialic acid and 
a CMP-sialic acid transporter have to be introduced 
to the system.  
 
Fig.2. N-glycosylation pathway in: (a) human and yeast (b) humanized Pichia pastoris [2]  
Fig.5. P.pastoris glycoengineering to produce 
complex human N-glycans. [5] 
CONSTRUCTION OF EXPRESSION 
STRAINS 
APPLICATION IN MONOCLONAL 
ANTIBODIES PRODUCTION 
• the insertion of the gene 
into an expression 
vector. 
• introduction of the 
expression vector into 
the P. pastoris genome. 
• examination of potential 
expression strains for 
the foreign gene 
product. 
   Alternative promoters non 
induced by methanol: GAP, 
FLD1, PEX8, and YPT1 
were found. 
 
HUMANIZING GLYCOSYLATION 
PATHWAY IN PICHIA PASTORIS 
EARLY APPROACHES 
Creation of och1 knockout strain 
Fig.6. Glycoengineering steps required for sialic acid transfer in the yeast Golgi.[6] 
Expression vectors 
Expression of any foreign gene in P. pastoris 
requires three basic steps: 
Fig.7. General diagram of a P. pastoris expression vector. YFG (Your Favorite Gene) 
sites for cassette amplification. [7] 
 
CONCLUSIONS 
 Compared to CHO cells, the glycoengineered yeast 
produced antibody with similar motilities on SDS-PAGE, 
comparable size exclusion chromatograms and antigen 
binding affinities but with highly uniform N-linked 
glycans of the type Man5GlcNAc2.  
 The production of monoclonal antibodies in P. Pastoris 
offers a robust and economically viable alternative to 
mammalian cell expression. 
 
Expression vectors are integrated into the P. 
pastoris genome to maximize the stability of 
expression strains. This can be done in two ways: 
• restricting the vector at a unique site in either the 
marker gene or the AOX1 promoter fragment and 
then to transform it. 
• digesting certain P. pastoris expression vectors in 
such a way that the expression cassette and 
marker gene are released, flanked by 5’ and 3’ 
AOX1 sequences. 
Multicopy strains can be approached: 
• Vector with multiple head-to-tail copies of an 
expression cassette flanked by restriction sites 
with complementary termini. 
• Expression vectors that contain the P. pastoris 
HIS4 and kanamycin resistance gene. 
• Vector with resistance to the antibiotic zeocin. 
Selectable markers 
• biosynthetic markers: HIS4, ARG4, ADE1, URA3 
• drug-resistance markers: kanR gene, Sh ble gene. 
Combinations of these different markers are 
employed for efficient selection of true 
transformants. 
Antibodies often achieve therapeutic benefit through two 
binding events: 
• the variable domain of the antibody binds a specific 
protein on a target cell. 
• the effector cells  bind to the constant region (Fc) of the 
antibody and destroy cells to which the antibody has 
bound. 
Construction of the antibody expression vector 
The plasmid pGLY2988 (containing IgG1 heavy and light 
chain under control of AOX1 promoter) was transformed 
into YGLY638 by electroporation to yield YGLY4140. 
The host strain has been modified to secrete recombinant 
proteins with highly uniform N-linked glycans of the 
type Man5GlcNAc2. 
